Your browser doesn't support javascript.
loading
The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma.
Zhang, Yan; Shi, Yuanfei; Shen, Huafei; Shou, Lihong; Fang, Qiu; Zheng, Xiaolong; Zhu, Mingyu; Huang, Xin; Huang, Jiansong; Li, Li; Zhou, De; Zhu, Lixia; Zhu, Jingjing; Ye, Xiujin; Jin, Jie; Xie, Wanzhuo.
Afiliación
  • Zhang Y; Department of Hematology, College of Medicine, Affiliated Huzhou Hospital, Zhejiang University, No. 1558 North Third Ring Road, Huzhou, 313000, Zhejiang, China.
  • Shi Y; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • Shen H; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • Shou L; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • Fang Q; Department of Hematology, College of Medicine, Affiliated Huzhou Hospital, Zhejiang University, No. 1558 North Third Ring Road, Huzhou, 313000, Zhejiang, China.
  • Zheng X; Department of Hematology, College of Medicine, Affiliated Huzhou Hospital, Zhejiang University, No. 1558 North Third Ring Road, Huzhou, 313000, Zhejiang, China.
  • Zhu M; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • Huang X; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • Huang J; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • Li L; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, 310003, Zhejiang, China.
  • Zhou; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • Zhu L; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, 310003, Zhejiang, China.
  • Zhu J; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • Ye X; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • Jin J; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • Xie W; Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
Cancer Cell Int ; 21(1): 573, 2021 Oct 29.
Article en En | MEDLINE | ID: mdl-34715862
ABSTRACT
Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Although a few prognostic models of PTCL have been established in retrospective studies, some high-risk patients still can not be screened out. Therefor we retrospectively studied 347 newly diagnosed PTCL patients and assessed the prognostic role of lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) in the complete response (CR) and survival of PTCL patients. Patients with LMR ≤ 1.68 and PMR ≤ 300 achieved a lower CR rate and a poor survival. In multivariate analysis, LMR ≤ 1.68 (HR = 1.751, 95% CI 1.158-2.647, p < 0.05) and PMR ≤ 300 (HR = 1.762, 95% CI 1.201-2.586, p < 0.05) were independently associated with short survival. On this basis, a new prognostic model of PTCL was established to screen out high-risk patients. In our "Peripheral Blood Score (PBS)" model, three groups were identified at low risk (178 patients, 51.3%, score 0), intermediate risk (85 patients, 24.5%, score 1), and high risk (84 patients, 24.2%, score 2), having a 1-year OS of 86%, 55.3% and 22.6% (p < 0.05), and a 3-year OS of 43.4%, 20% and 13.1% (p < 0.05), respectively. Optimal strategies for identifying high-risk patients with PTCL are urgently needed. Our new PBS model is simple, inexpensive and widely available to screen out the high risk patients.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancer Cell Int Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancer Cell Int Año: 2021 Tipo del documento: Article País de afiliación: China